Development, optimization and evaluation of polymeric electrospun nanofiber: A tool for local delivery of fluconazole for management of vaginal candidiasis

Figures & data

Table I. Optimization parameters and microscope observations of different trials.

Formulation code	PVA concentration (% w/v)	Potential applied (kV)	Flow rate (ml/h)	TCD (cms)	Observations
R1	10	10	0.1	12	High density, non-continuous, thick, beads
R2	10	12	0.1	12	High density, continuous, no beads, thick
R3	10	14	0.1	12	High density, continuous, thin, no beads
R4	10	10	0.1	15	Low density, continuous, thin, beads
R5	10	12	0.1	15	Medium density, continuous, thick, no beads
R6	10	14	0.1	15	High density, non-continuous, beads, thin
R7	10	10	0.1	18	Low density, non-continuous, thin, no beads
R8	10	12	0.1	18	Medium density, continuous, thin, beads
R9	10	14	0.1	18	Medium density, continuous, thick, no beads

Figure 1. Optical microscopy images of drug-loaded PVA nanofibers at 10 (a), 40 (b) and 100 X (c) showing presence of beads in the nanofibers.

Figure 2. SEM images of blank nano fibers.

Figure 3. SEM images of drug-loaded nanofibrous mat.

Figure 4. The IR overlay spectra of PVA polymer, fluconazole and drug-loaded nanofibers.

Figure 5. DSC of drug-loaded nanofibers.

Figure 6. Graphic representation of the swelling index of blank and drug-loaded nanofibers.

Figure 7. Drug release profile of PVA drug-loaded nanofibers.

Table II. Table showing zones of inhibition of various formulations on Candida albicans and Lactobacillus acidophilus.

Formulation	Zone of inhibition(diameter) in candida albicans (cm)				Zone of inhibition(diameter) in lactobacillus acidophilus (cm)
	After 12 h	After 24 h	After 48 h	After 72 h	After 12 h	After 24 h	After 48 h
Plain drug	0.8	1.4	1.4	1.2	–	–	–
Nanofibers	2.9	4.1	4.9	4.8	–	–	–